Key Drivers
- Strong liquidity
- Zero revenue
- High cash burn
AIAI Summary
Allogene has shifted from a binary platform gamble to a capital‑disciplined, catalyst‑driven developer whose valuation now depends tightly on a few near‑term readouts (ALPHA3 MRD futility and autoimmune PoC) and maintaining cash discipline (runway into 2027–Q1 2028)—a positive MRD signal could materially re‑rate the stock, while MRD failure, CMC setbacks, or dilutive financing would rapidly compress value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenue
- •High cash burn
ALLO has strong liquidity and virtually no debt but generated zero revenue with steep R&D-driven operating losses and heavy negative free cash flow, leaving its ~ $602M market valuation exposed to execution risk.
Price Behavior
Key Price Behavior Insights:
- •Lower highs/lows
- •Volatile pullbacks
- •Repeated bounces
ALLO has weakened over the last month, sliding about 19% from $2.78 to $2.26 with lower highs/lows and failed rallies, testing support near $2.05–$2.15 while needing a clear break above $2.65–$2.78 to reverse.
~19% drop from $2.78 to $2.26 over the last month with an intermediate failed rally
Sentiment & News
Key News Insights:
- •Cost reductions
- •AlloCAR T progress
- •Rising short interest
Allogene narrowed Q4 losses, cut expenses and advanced AlloCAR T programs with cash runway into 2028, even as short interest surged sharply.
Operational improvements and extended runway lower near-term dilution risk, but elevated short interest could keep downward pressure until clearer clinical or financial catalysts emerge
Similar Companies in Healthcare
Other companies in the same sector with AI ratings